ImmunoCellular Therapeutics receives U.S. patent for cancer vaccine technology

Published on June 22, 2011 at 2:35 AM · No Comments

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular Therapeutics" or the Company")(OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced the issuance of a U.S. patent relating to a technology for the treatment of cancer for which the Company holds an exclusive, worldwide license. Patent No. 7,939,090, entitled "System and method for the treatment of cancer, including cancers of the central nervous system," covers the combination of a dendritic cell based vaccine combined either before or concurrently with chemotherapy at the recurrence of the disease. The Company believes that in the treatment of cancer, particularly cancers of the central nervous system such as glioblastoma multiforme (GBM), a dual therapeutic approach that includes the administration of a dendritic cell-based cancer vaccine combined with a regimen of chemotherapy could substantially enhance the clinical efficacy of treatment.

"This patent has applicability to multiple types of cancer, including our first clinical target, glioblastoma," said Manish Singh, Ph.D. president and CEO of ImmunoCellular Therapeutics. "ICT-107, the Company's dendritic cell based vaccine candidate for the treatment of GBM, elicits a cytotoxic tumor reactive response that in combination with chemotherapy might fundamentally alter tumors by priming their death machinery."

ImmunoCellular Therapeutics recently announced the expansion of its Phase II trial of ICT-107 from up to 15 clinical centers to 20 or more. The Phase II trial of ICT-107 is a double-blind, placebo-controlled, 2:1 randomized study designed to evaluate the safety and efficacy of ICT-107 in patients with newly diagnosed GBM. The study is enrolling patients at medical institutions in collaboration with well known experts and opinion leaders in neuro-oncology at those sites.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | हिन्दी | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post